This report analyzes the Global market for G-Protein Coupled Receptors (GPCRs) in US$ Billion. Annual estimates and forecasts are provided for the period 2009 through 2017. Also, a six-year historic analysis is provided for this market. The report profiles 43 companies including 7TM Pharma A/S, Actelion Pharmaceuticals Ltd., Acure Pharma AB, Anchor Therapeutics, Arena Pharmaceuticals, Inc., Addex Pharmaceuticals, Acadia Pharmaceuticals Inc., Cara Therapeutics, Inc., DiscoveRx Corporation, Dimerix Bioscience Pty Ltd., Domain Therapeutics, Euroscreen SA, and Trevena, Inc. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based upon search engine sources in the public domain.
Table of Contents
Table of Contents
I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS
Study Reliability and Reporting Limitations
Disclaimers
Data Interpretation & Reporting Level
Quantitative Techniques & Analytics
Product Definitions and Scope of Study
II. EXECUTIVE SUMMARY
1. INDUSTRY OVERVIEW
A Quick Primer
Why GPCRs Are Important?
Illustrative Examples of Currently Available Pharmaceutical Drugs Targeting GPCRs
Untapped Pharmacological Potential of GPCRs Ignites Interest
Popular Types of GPCRs of Therapeutic Interest Currently Being Studied Include:
Current Knowledge of GPCR Crystal Structures Just the Tip of the Iceberg
NMR Spectroscopy: An Invaluable Tool to Study GPCR Structures
Orphan GPCRs: A Promising Area for Drug Discovery
Developments in Screening Technology for GPCRs
Cell Membrane Assays for GPCR Quantitative Analysis
What's in for the Pharmaceutical Industry?
Challenges Aplenty in the GPCR Space
Addressing Orphan GPCRs
Lack of Structural Information
Identification and Classification of Allosteric Sites
2. G-PROTEIN COUPLED RECEPTORS (GPCR) - A CONCEPTUAL OVERVIEW
GPCR: Gateways to Cell
Classification of GPCRs
Table 1: List of Identified Known and Orphan (Non-Sensory) GPCRs in Human Genome (includes corresponding Graph/Chart)
Orphan GPCRs and Deorphanization
List of oGPCR-Ligand Pairings Identified By Using Reverse Pharmacology Approach
Structural Information
Rhodopsin: A Well Studied GPCR
Crystal Structure of Human Beta-2 Adrenergic GPCR
Structure of Human A2A Adenosine Receptor
Significance of GPCR Crystal Structures
GPCR Signaling Pathways
Physiological Roles Performed by GPCRs
Visual Sense
Cell-density Sensing
Regulation of mood and behavior
Smelling Sense
Regulating Immune-System Inflammation and Activity
Automatic Transmission of Nervous System
Receptor - Ligand Interaction
Types of Ligands
Therapeutic Potential of GPCRs
List of Major Disease States and Associated Known GPCRs
Allosteric Modulators and Implication of Allostery in Drug Discovery
Advantages of Allosteric Modulators
Dimerisation and Role of Dimers in Drug Discovery
Oligomerisation and Role of Oligomers in Drug Discovery
Functional Selectivity
Existing Drug Candidates in GPCR Space
List of Existing GPCR-Based Drugs Available In Market Along With Their Target Receptor and Indication
Pipeline GPCR Drug Candidates
Ion Channels
Approaches to Drug Discovery in GPCR Space
Structure-Based Drug Discovery
Ligand-Based Drug Discovery
Target-Based Drug Discovery
GPCR Screening and Targeting Technologies
Cell-Based Screening Assays
Virtual Screening
Fragment screening
3. RECENT INDUSTRY ACTIVITY
Domain Therapeutics Enters into an Agreement with Merck Serono
Anchor Therapeutics Makes a Breakthrough in GPCR Collaboration
Receptos Collaborates with Lilly GPCR target
Sanofi-aventis Enters into Licensing Agreement with Metabolex
Neurocrine and Boehringer Ingelheim Join Hands to Develop GPR119 Agonists
Affitech Enters into Research Collaboration with NTS Plus
Takeda Cambridge Inks an Agreement to Utilize Dimerix' GPCR-HIT Platform
PerkinElmer Unveils New Detection Kit for Profiling and Screeing GPCRs
Omeros Completes Acquisition of GPCR Assay Technology from Patobios
DiscoveRx Corporation Takes Over KINOMEscan™
Roche and ATCC Collaborate on Real-Time Endogenous GPCR Function Research
BioFocus and Amgen Extend Drug Discovery Agreement
DiscoveRx Selects Cosmo Bio to Distribute GPCR Profiling Service across Japan
Euroscreen Extends Agreement with Cephalon
BioFocus DPI Introduces Novel Version of GPCR SARfari
PerkinElmer Takes Over Euroscreen Products
4. FOCUS ON SELECT GLOBAL PLAYERS
7TM Pharma A/S (Denmark)
Actelion Pharmaceuticals Ltd. (Switzerland)
Acure Pharma AB (Sweden)
Anchor Therapeutics (USA)
Arena Pharmaceuticals, Inc. (US)
Addex Pharmaceuticals (Switzerland)
Acadia Pharmaceuticals Inc., (USA)
Cara Therapeutics, Inc. (USA)
DiscoveRx Corporation (USA)
Dimerix Bioscience Pty Ltd (Australia)
Domain Therapeutics (France)
Euroscreen SA (Belgium)
Trevena, Inc. (USA)
5. GLOBAL MARKET PERSPECTIVE
Table 2: World Recent Past, Current & Future Market Analysis for G-Protein Coupled Receptors (GPCRs) Targeting Drugs Analyzed with Annual Sales Figures in US$ Billion for Years 2009 through 2017 (includes corresponding Graph/Chart)
Table 3: World Historic Review for G-Protein Coupled Receptors (GPCRs) Targeting Drugs Analyzed with Annual Sales Figures in US$ Billion for Years 2003 through 2008 (includes corresponding Graph/Chart)
IV. COMPETITIVE LANDSCAPE
G-Protein Coupled Receptors (GPCRs) published by Global Industry Analysts, Inc. in April 1, 2012. This report consists of Pages: 299 and the price starts from US $ 4500.
The contents of this page may be different from the latest version. Please contact us for details.
